A Phase 3 interventional study of PEG-Intron™ and PEGASYS™ in Hepatitis B, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic — 5 open to participants now, 5 under way, none of them phase 3. peginterferon alfa-2b · Hepatitis B, Chronic.
Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 5th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →5 of the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–60
Beijing Ditan Hospital · Sites in China
Ages 18–65 · Women only
Ningbo No.2 Hospital · Sites in China
Ages 18–65
Nanfang Hospital, Southern Medical University · Sites in China
Ages 3–18
Huashan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 5 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2012.
This study's enrollment of 402 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 254 across the 15 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 3 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing peginterferon alfa-2b in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05182463Third Affiliated Hospital, Sun Yat-Sen UniversityPeginterferon Treatment Study for Inactive Chronic Hepatitis B Patients | 2026-12-13 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been treated with interferon.
Inclusion Criteria:
method of from at least 2 weeks prior to Day 1 and continue until at least 1 month after last dose of study drug
Inclusion Criteria for HBeAg(+) participants:
Inclusion Criteria for HBeAg(-) participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
Biological: PEG-Intron™
HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
Biological: PEGASYS™
HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
Biological: PEG-Intron™
HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
Biological: PEGASYS™
PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
Also known as: SCH 054031, Pegylated interferon alfa-2b
PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
Also known as: Pegylated interferon alfa-2a
Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment
Blood samples were drawn to assess the participant's seroconversion status at Follow-up (FU) Week 24. HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.
Time frame: FU Week 24 (Study Week 72)
Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(-) participants. The percentage of HBeAg(-) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.
Time frame: FU Week 24 (Study Week 72)
Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(+)participants. The percentage of HBeAg(+) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.
Time frame: FU Week 24 (Study Week 72)
Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment
ALT normalization is a desired goal of HBV treatment, which is defined as having abnormal ALT levels at baseline and subsequently normal ALT levels after receiving treatment, where normal is defined as ≤ 1x the upper limit of normal (ULN). The percentage of HBeAg(+) and HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment was reported.
Time frame: FU Week 24 (Study Week 72)
Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg. HBV DNA levels in blood were measured by the Roche COBAS TaqMan HBV-(High Pure System Assay). The percentage of HBeAg(+) participants with the combined response of achieving both HBeAg conversion and HBV DNA levels \<2000 IU/mL at 24 weeks post-treatment was reported.
Time frame: FU Week 24 (Study Week 72)
Hepatitis B envelope antigen (HBeAg)-positive or -negative participants who were interferon treatment-naïve were recruited from 81 sites to be randomly assigned to receive pegylated inferferon alfa-2b (PEG-Intron™) or pegylated interferon alfa-2a (PEGASYS™).
| Milestone | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Started | 143 | 145 | 57 | 57 |
| Treated (all participants as treated) | 142 | 144 | 56 | 57 |
| Completed | 115 | 130 | 46 | 53 |
| Not completed | 28 | 15 | 11 | 4 |
| Withdrew: Adverse event | 5 | 2 | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 0 |
| Withdrew: Physician decision | 6 | 5 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 13 | 5 | 6 | 1 |
| Withdrew: Not treated | 1 | 1 | 1 | 0 |
Blood samples were drawn to assess the participant's seroconversion status at Follow-up (FU) Week 24. HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.
| percentage of participants | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment | 25.4 | 23.6 | — | — |
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(-) participants. The percentage of HBeAg(-) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.
| percentage of participants | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment | — | — | 30.4 | 33.3 |
The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(+)participants. The percentage of HBeAg(+) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.
| percentage of participants | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment | 23.9 | 21.5 | — | — |
ALT normalization is a desired goal of HBV treatment, which is defined as having abnormal ALT levels at baseline and subsequently normal ALT levels after receiving treatment, where normal is defined as ≤ 1x the upper limit of normal (ULN). The percentage of HBeAg(+) and HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment was reported.
| percentage of participants | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment | 49.3 | 47.2 | 71.4 | 61.4 |
HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg. HBV DNA levels in blood were measured by the Roche COBAS TaqMan HBV-(High Pure System Assay). The percentage of HBeAg(+) participants with the combined response of achieving both HBeAg conversion and HBV DNA levels \<2000 IU/mL at 24 weeks post-treatment was reported.
| percentage of participants | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS |
|---|---|---|---|---|
| Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment | 14.8 | 13.9 | — | — |
Collected over SAEs up to 30 days after Week 24 Post-Treatment Visit (up to 76 weeks) Nonserious AEs up to Treatment Week 48 (up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HBeAg(+) PEG-Intron | — | 12/142 (8.5%) | 126/142 (88.7%) |
| HBeAg(+) PEGASYS | — | 10/144 (6.9%) | 124/144 (86.1%) |
| HBeAg(-) PEG-Intron | — | 1/56 (1.8%) | 50/56 (89.3%) |
| HBeAG(-) PEGASYS | — | 2/57 (3.5%) | 50/57 (87.7%) |
| Event | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAG(-) PEGASYS |
|---|---|---|---|---|
| MenorrhagiaReproductive system and breast disorders | 0/142 | 0/144 | 1/56 | 0/57 |
| Gallbladder polypHepatobiliary disorders | 0/142 | 0/144 | 0/56 | 1/57 |
| HepatitisHepatobiliary disorders | 1/142 | 1/144 | 0/56 | 1/57 |
| DyspepsiaGastrointestinal disorders | 0/142 | 2/144 | 0/56 | 0/57 |
| Alanine aminotransferase increasedInvestigations | 0/142 | 2/144 | 0/56 | 0/57 |
| Basedow's diseaseEndocrine disorders | 1/142 | 0/144 | 0/56 | 0/57 |
| Retinal vein occlusionEye disorders | 1/142 | 0/144 | 0/56 | 0/57 |
| Duodenal perforationGastrointestinal disorders | 1/142 | 0/144 | 0/56 | 0/57 |
| AstheniaGeneral disorders | 1/142 | 0/144 | 0/56 | 0/57 |
| PyrexiaGeneral disorders | 1/142 | 0/144 | 0/56 | 0/57 |
| Event | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAG(-) PEGASYS |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 66/142 | 55/144 | 21/56 | 20/57 |
| AlopeciaSkin and subcutaneous tissue disorders | 57/142 | 54/144 | 18/56 | 14/57 |
| MyalgiaMusculoskeletal and connective tissue disorders | 43/142 | 35/144 | 21/56 | 13/57 |
| HeadacheNervous system disorders | 48/142 | 35/144 | 16/56 | 14/57 |
| FatigueGeneral disorders | 37/142 | 30/144 | 10/56 | 9/57 |
| Influenza like illnessGeneral disorders | 17/142 | 19/144 | 6/56 | 11/57 |
| Weight decreasedInvestigations | 9/142 | 16/144 | 9/56 | 4/57 |
| Decreased appetiteMetabolism and nutrition disorders | 17/142 | 21/144 | 5/56 | 6/57 |
| PruritusSkin and subcutaneous tissue disorders | 9/142 | 14/144 | 7/56 | 6/57 |
| Injection site reactionGeneral disorders | 9/142 | 2/144 | 6/56 | 0/57 |
All Participants as Treated (APaT: all randomized participants who received ≥1 dose of study medication
| Age, Continuous(years) | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS | Total |
|---|---|---|---|---|---|
| Mean | 32.6 ± 7.73 | 33.6 ± 9.23 | 41.1 ± 10.77 | 42.0 ± 10.50 | 35.5 ± 9.91 |
| Sex: Female, Male(Participants) | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS | Total |
|---|---|---|---|---|---|
| Female | 54 | 43 | 21 | 15 | 133 |
| Male | 88 | 101 | 35 | 42 | 266 |
| Race/Ethnicity, Customized(participants) | HBeAg(+) PEG-Intron | HBeAg(+) PEGASYS | HBeAg(-) PEG-Intron | HBeAg(-) PEGASYS | Total |
|---|---|---|---|---|---|
| Asian | 142 | 144 | 56 | 57 | 399 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Nov 2012 to primary completion in Jan 2016, 37 months.
Results were first posted in Jan 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b